Ranbaxy has completed 20 successful years in Russia. The company established its operations in the Russian market in 1993 with the launch of its key brand, Cifran. Since then, Ranbaxy has grown to become number one player with a market share of 15.4 per cent in the represented market segment in Russia (IMS, May 2013).
Ranbaxy today has operations in 56 regions of Russia. The company has a portfolio of products covering anti-infective, cold, pain management, cardiovascular, diabetology, central nervous system, urology and dermatology segments. So far, the company has registered 51 drugs in the Russian Federation and commercialised 72 SKU’s. Ranbaxy’s leading brands in Russia include Ketanov, Coldact, Faringosept, Cifran, Pylobact and Fenules. Last year, Faringosept was selected as the People’s brand of choice. Another brand, Cifran OD was ranked by IMS as the best antibiotic launch in 2004.
Arun Sawhney, Chief Executive Officer and Managing Director, Ranbaxy said, “Ranbaxy was one of the first pharma companies from India to set up operations in Russia. We have been providing high quality, affordable generic medicines to the citizens of Russia for the last two decades, thereby supporting the Government to bring down healthcare costs. We remain committed to the Russian market and will continue to operate from the paradigm of Quality and Patients First”.
Aman Khanna, Country Head of Russia, Ranbaxy, said, “Over the years, Ranbaxy has established itself as a preferred generic pharma company in Russia. In the coming years, we look at further expanding our product portfolio to include value added and innovator products from our parent company, Daiichi Sankyo. We are working closely in partnership with regional governments in line with the Russia Pharma, 2020 Healthcare Plan.”
EP News Bureau – Mumbai
